Research hotspots and trends of epigenetic therapy in oncology: a bibliometric analysis from 2004 to 2023
In the past two decades, the importance of epigenetic therapy in cancer research has become increasingly prominent. The United States occupies a key position in this field, while China, despite having published a large number of related papers, still has relatively limited influence. Current research focuses on the "combination therapy" of epigenetic drugs. Future studies should further explore the sequencing and scheduling of combination therapies, optimize trial designs and dosing regimens to improve clinical efficacy.
Authors
- Dongping Jiang
- Qing Shao (ORCID: https://orcid.org/0000-0002-4507-3786)
- Sisi Li (ORCID: https://orcid.org/0000-0002-4862-8740)
- Xinrui Liang
- Ping Wen (ORCID: https://orcid.org/0000-0002-3282-7083)
- Yuxin Huang (ORCID: https://orcid.org/0000-0003-3056-4168)
- Guanwen Wang (ORCID: https://orcid.org/0000-0001-7026-5854)
- Xiaohua Zeng
Institutions
- Chongqing University (CN)
- Chongqing Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-09-12
- DOI
- https://doi.org/10.3389/fphar.2024.1465954
- Citations
- 3
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 0.70
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing